The Biden administration appealed a 2023 jury decision, which found that Gilead did not infringe on key government patents in its HIV prevention regimen consisting of the drugs Truvada and Descovy.
Tag Archive for: Truvada
Gilead Sciences’ antiviral demonstrated 100% efficacy for HIV prevention in cisgender women in Phase III trial results announced Thursday.
A Delaware jury ruled in favor of Gilead Sciences, finding that the company’s HIV prevention medicines Truvada and Descovy do not infringe on U.S. government patents and that the patents themselves are invalid in the first place. The company also announced it was acquiring private San Diego biotech XinThera.
Gilead Sciences is headed to trial in Delaware federal court this week to fight claims that it owes the U.S. government a share of multibillion-dollar profits from its HIV-prevention drug regimen.